Patients with systemic sclerosis and low CD4 numbers after autologous stem cell transplantation have a favorable outcome

Ann-Christin Pecher,Reinhild Klein,Ina Koetter,Marieke Wagner,Wichard Vogel,Stefan Wirths,Claudia Lengerke,Joerg Christoph Henes

DOI: https://doi.org/10.1186/s13075-024-03300-1

2024-03-20

Arthritis Research & Therapy

Abstract:Treatment with high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (aHSCT) is an intensive treatment option for patients with severe forms of systemic sclerosis (SSc). Even though associated with a high treatment related mortality, the results in this high-risk population are generally favourable. The knowledge on the potential mechanism of action of this therapy and how it can improve patients with SSc is crucial to better select the right patients for aHSCT.

rheumatology